X-linked hypophosphataemia
Rare disease · 2021–2022
3decisions
1medicine
3carried consumer input
498individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| burosumab Treatment of X-linked hypophosphataemia (XLH) in paediatric and adult patients with confirmed PHEX pathogenic variant or clinical/laboratory criteria including… | May 2022 | Recommended with restriction | 175 individuals Australasian Paediatric Endocrine Group |
| burosumab X-linked hypophosphataemia (XLH) in paediatric and adult patients aged 1 year and above. | Mar 2022 | Not recommended | 175 individuals Australasian Paediatric Endocrine Group |
| burosumab Treatment of X-linked hypophosphataemia (XLH) in paediatric patients (aged less than 18 years) with a confirmed diagnosis. | Mar 2021 | Not recommended | 148 individuals XLH Australia · Australasian Paediatric Endocrine Group |
Who spoke
Australasian Paediatric Endocrine Group · XLH Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.